(NASDAQ: SGP) Spyglass Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.41%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.85%.
Spyglass Pharma's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast SGP's earnings for 2026 to be -$79,775,328, with the lowest SGP earnings forecast at -$95,017,595, and the highest SGP earnings forecast at -$73,018,447. On average, 6 Wall Street analysts forecast SGP's earnings for 2027 to be -$90,708,035, with the lowest SGP earnings forecast at -$127,454,636, and the highest SGP earnings forecast at -$63,225,818.
In 2028, SGP is forecast to generate -$109,484,208 in earnings, with the lowest earnings forecast at -$196,915,774 and the highest earnings forecast at -$61,748,063.